True to its word, the Trump administration released its 2018 budget that includes a notable change for drug and device makers — they would face a stiff increase in so-called user fees that industry pays for to fund product reviews conducted by the Food and Drug Administration. And the higher fees, which are slated to nearly double to $2.4 billion, would be used to cover the entire cost of those reviews (see page 39).

The notion was widely anticipated after a May 15 letter, which written by US Health and Human Services Secretary Tom Price to the Senate Health, Education, Labor, and Pensions Committee, leaked out. The administration, he wrote, “is seeking to recalibrate how the FDA finances its medical product review work in order to better serve the American people.”

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy